Keros Therapeutics, Inc. (KROS) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
KROS Revenue Growth
Revenue Breakdown (FY 2025)
KROS's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
KROS Revenue Analysis (2018–2025)
As of May 8, 2026, Keros Therapeutics, Inc. (KROS) generated trailing twelve-month (TTM) revenue of $244.1 million, reflecting significant decline in growth of -87.3% year-over-year. The most recent quarter (Q4 2025) recorded $385,000 in revenue, down 97.3% sequentially.
Looking at the longer-term picture, KROS's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $244.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows KROS's business is primarily driven by License (84%), and Service, Other (16%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including KRYS (+25.1% YoY), DAWN (+20.6% YoY), and BEAM (+108.0% YoY), KROS has underperformed the peer group in terms of revenue growth. Compare KROS vs KRYS →
KROS Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| KROSCurrent | $244M | -87.3% | - | 28.9% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 DAWN | $158M | +20.6% | - | -80.8% | |
 BEAM | $140M | +108.0% | +466.3% | -274.6% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
KROS Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $244.1M | +6775.0% | $242.6M | 99.4% | $70.6M | 28.9% |
| 2024 | $3.5M | +2251.0% | $3.5M | 100.0% | $-210,833,000 | -5939.0% |
| 2023 | $151K | - | $151K | 100.0% | $-169,941,000 | -112543.7% |
| 2022 | $0 | -100.0% | $0 | - | $-114,790,000 | - |
| 2021 | $20.1M | - | $20.1M | 100.0% | $-56,373,000 | -280.5% |
| 2020 | $0 | -100.0% | $-605,000 | - | $-46,657,000 | - |
| 2019 | $10.0M | +0.0% | $-7,348,000 | -73.5% | $-10,563,000 | -105.6% |
| 2018 | $10.0M | - | $-111,000 | -1.1% | $-1,691,000 | -16.9% |
See KROS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs KROS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare KROS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonKROS — Frequently Asked Questions
Quick answers to the most common questions about buying KROS stock.
Is KROS's revenue growth accelerating or slowing?
KROS revenue declined -87.3% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $244M. This reverses the prior growth trend.
What is KROS's long-term revenue growth rate?
Keros Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -87.3% is below this long-term average.
How is KROS's revenue distributed by segment?
KROS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.